Streetbeat News

Revenues

OMCL

Omnicell has announced its expectations for the fourth quarter of 2024, projecting total revenues between $295 million and $305 million, surpassing the estimated $287.89 million. The company also anticipates adjusted EPS between $0.55 and $0.62, exceeding the estimated $0.47.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:38 am

CMCO

Columbus McKinnon has issued its fiscal year 2025 guidance, projecting flat to low-single digit revenue growth and mid-single digit adjusted EPS growth. The company plans capital expenditures of $20-25 million and expects a net leverage ratio of approximately 2.3x.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:38 am

CMCO

Columbus McKinnon has issued guidance for Q3 FY25, expecting flat year-over-year growth in both net sales and adjusted EPS. The company anticipates $8 million in interest expense, $8 million in amortization, a 25% tax rate, and 28.9 million diluted shares outstanding.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:37 am

OMCL

Omnicell has updated its 2024 financial guidance, projecting revenues between $1.10B and $1.11B, slightly above the previous range. Adjusted EPS is expected to be between $1.65 and $1.72, higher than prior estimates. The company cites strong performance in the first three quarters of 2024.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:36 am

OMF

OneMain Holdings reported Q3 earnings of $1.26 per share, beating estimates but showing a decline from last year. Sales were $972 million, missing expectations but up from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:35 am

CVEO

Civeo projects its FY24 revenue to be between $675M and $700M, with an adjusted EBITDA of $83M to $88M. The company maintains its capital expenditures guidance at $30M to $35M.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:35 am

WRK

Smurfit Westrock anticipates a combined adjusted EBITDA of approximately $4.7 billion for the full year 2024.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:35 am

ZBH

Zimmer Biomet has revised its financial guidance for FY24, lowering its adjusted EPS forecast to $7.95-$8.05 from $8.00-$8.15 and reducing its revenue growth projection to 3.5%-4% from 4%-5%.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:33 am

TECH

Bio-Techne reported its Q1 2025 financial results, with adjusted EPS of $0.42 beating the estimate of $0.38, and sales of $289.458 million surpassing the expected $280.260 million.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:32 am

ZBH

Zimmer Biomet Holdings reported Q3 2024 earnings per share of $1.74, meeting analyst expectations, and sales of $1.824 billion, surpassing estimates. This represents a year-over-year increase in earnings and sales.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 10:31 am